NaNotics Study Demonstrates New Nanotechnology Approach to Cancer Immunotherapy
Peer-reviewed research shows engineered nanoparticles can selectively deplete soluble PD-L1, restore antitumor immunity and substantially delay tumor growth.
New peer-reviewed research from Mayo Clinic and NaNotics LLC demonstrates a novel approach to cancer immunotherapy: engineered adsorptive nanoparticles called NaNots® selectively deplete a soluble protein that tumors use to suppress immune response and enable tumor growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909077651/en/ Inside NaNots
In the study, “Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control,” published in the International Journal of Nanomedicine, NaNots engineered to deplete soluble PD-L1 (sPD-L1) restored antitumor immunity and substantially delayed tumor growth in a humanized mouse model of triple-negative breast cancer, a notoriously difficult cancer to treat. The new study is proof-of-concept that depleting just the soluble form of an immune checkpoint protein from circulation – without targeting the tumor directly – can reduce tumor-driven immune suppression and control tumor growth.
